Financial Survey: Vivos Therapeutics (NASDAQ:VVOS) & PMV Pharmaceuticals (NASDAQ:PMVP)

Vivos Therapeutics (NASDAQ:VVOS) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Vivos Therapeutics has a beta of 6.25, meaning that its stock price is 525% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Vivos Therapeutics and PMV Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.60	-$21.17 million	($2.07)	-0.37
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.49)	-0.91

Vivos Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vivos Therapeutics and PMV Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-121.37%	-849.22%	-96.11%
PMV Pharmaceuticals	N/A	-59.07%	-54.19%

Analyst Recommendations

This is a summary of current ratings and price targets for Vivos Therapeutics and PMV Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	2	2	0	2.20
PMV Pharmaceuticals	1	0	0	1	2.50

Vivos Therapeutics currently has a consensus price target of $2.58, indicating a potential upside of 239.91%. PMV Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 266.84%. Given PMV Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Vivos Therapeutics.

Summary

PMV Pharmaceuticals beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.